Objective: To investigate the seroprevalence of Toxoplasma gondii infection in patients with gynecological malignant tumors, so as to provide the evidence for the control of T. gondii infections in the patients with gynecological malignant tumors.
Methods: A total of 327 patients with gynecological malignant tumors were recruited, and 200 women with normal healthy examinations were served as controls. The serum anti-T. gondii IgG and IgM antibodies were detected by using ELISA, and the seroprevalence was compared between the patients and controls, and among various types of cancers.
Results: The overall seroprevalence of T. gondii was 26.91% (88/327) in the patients with gynecological malignant tumors, which was significantly higher than that (5.00%) in the healthy volunteers (χ2 = 39.36, P<0.01) . The prevalence of anti-T. gondii IgG antibody in the cancer patients was significantly higher than that in the controls (26.30% vs. 5.00%; χ2 = 37.79, P<0.01), while the prevalence of anti-T. gondii IgM antibody in the cancer patients was not significantly different from that in the controls (0.92% vs. 0; corrected χ2 = 0.58, P > 0.01) . The positive rates of anti-T. gondii IgG antibody were 27.68%, 25.47% and 25.69% in ovarian cancer, cervical cancer, and breast cancer patients respectively, which were all significantly higher than those in the controls (χ2 = 32.35, 27.32 and 28.00; all P values<0.01); however, there was no significant difference among the various types of cancer patients in the positive rates of anti-T. gondii IgG antibody (χ2 = 0.17, P > 0.05) . In addition, the positive rates of anti-T. gondii IgM antibody were 1.79%, 0 and 0.92% in ovarian cancer, cervical cancer and breast cancer patients respectively, which was not significantly different from those in the controls (all P values > 0.05).
Conclusions: The seroprevalence of T. gondii infection is high in the patients with gynecological malignant tumors. It is suggested that the prevention and control of T. gondii infection should be strengthened in these patients.
[摘要] 目的 了解妇科恶性肿瘤患者弓形虫感染情况, 为后续该类人群弓形虫感染防控提供依据。方法 收集 327 例临床妇科恶性肿瘤患者血清样本, 同时收集 200 例女性体检正常者血清作为对照, 采用酶联免疫吸附试验 (ELISA) 检 测血清抗弓形虫IgG和IgM抗体, 分析不同人群抗弓形虫抗体阳性率差异。结果 327 例妇科恶性肿瘤患者总体弓形虫 感染率为 26.91% (88/327), 高于健康体检者的 5.00% (χ2 = 39.36, P<0.01); 其中血清抗弓形虫IgG抗体阳性率高于健康 体检者 (26.30% vs. 5.00%; χ2 = 37.79, P<0.01), 血清抗弓形虫IgM抗体阳性率与健康体检者差异无统计学意义 (0.92% vs. 0; 校正χ2 = 0.58, P > 0.01)。卵巢癌、子宫颈癌和乳腺癌患者血清抗弓形虫IgG抗体阳性率分别为 27.68%、 25.47%和 25.69%, 均高于健康体检者 (χ2 = 32.35 、 27.32 、 28.00, P 均< 0.01), 但卵巢癌、子宫颈癌和乳腺癌患者血清抗弓形虫IgG抗 体阳性率差异无统计学意义 (χ2 = 0.17, P > 0.05)。卵巢癌、子宫颈癌和乳腺癌患者血清抗弓形虫IgM抗体阳性率分别为 1.79%、 0 和 0.92%, 与健康体检者差异均无统计学意义 (P 均> 0.05)。结论 妇科恶性肿瘤患者弓形虫感染率较高, 应加 强妇科恶性肿瘤患者弓形虫感染防控。.
Keywords: Gynecological malignant tumor; Seroepidemiological survey; Toxoplasma gondii.